Stentys S.A.S. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
11,728.70
17,834.00
9,459.00
8,359.00
5,870.00
5,398
Depreciation, Depletion & Amortization
250.20
419.00
1,013.00
1,267.00
740.00
1,852
Other Funds
210.30
3,550.00
901.00
1,797.00
147.00
98
Funds from Operations
11,268.30
13,865.00
9,347.00
8,889.00
4,983.00
4,338
Changes in Working Capital
1,067.40
50.00
2,062.00
3,557.00
3,258.00
1,073
Net Operating Cash Flow
12,335.70
13,815.00
11,409.00
5,332.00
8,241.00
3,265
Capital Expenditures
1,151.30
398.00
20.00
79.00
91.00
Purchase/Sale of Investments
58.70
30.00
534.00
127.00
144.00
Net Investing Cash Flow
1,202.20
790.00
547.00
86.00
63.00
Issuance/Reduction of Debt, Net
290.30
320.00
-
-
8.00
Net Financing Cash Flow
218.70
1,320.00
3,983.00
11,577.00
8.00
Net Change in Cash
13,758.40
13,265.00
7,952.00
6,332.00
8,194.00
Free Cash Flow
12,397.80
13,856.00
11,415.00
5,410.00
8,289.00
Other Sources
7.70
38.00
7.00
38.00
10.00
Change in Capital Stock
71.70
1,640.00
3,983.00
11,577.00
-
Exchange Rate Effect
1.90
20.00
21.00
1.00
8.00
Other Uses
-
400.00
-
-
-

About Stentys

View Profile
Address
18, rue d' Hauteville
Paris Ile-de-France 75010
France
Employees -
Website http://www.stentys.com
Updated 07/08/2019
Stentys SA engages in the design, development and marketing of self-expanding stents used in treating cardiovascular diseases. It provides innovative solutions to the interventional cardiologist to treat patients with acute myocardial infarction and other complex coronary disease. The company's products include xpositions, mistent, stentys btk, stentys ac, ses stent and stentys stent.